|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | ||
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation and Amortization | ||
| Fair value adjustments of Convertible loans | ||
| Fair value adjustments of derivative liability - Warrants | ||
| Re-assessment of Liability for Agricultural Research Organization | ||
| Interest over Agricultural Research Organization liability | ||
| Finance expense (income), net | ||
| Share based compensation | ||
| Adjustments for changes in working capital | ||
| Change in Trade accounts receivable | ||
| Change in Other accounts receivable | ||
| Change in Inventory | ||
| Changes in Trade accounts payable, Other accounts payable and Accrued liabilities | ||
| Changes in deferred revenue | ||
| Interest paid | ||
| Net cash used in operating activities | ||
| Cash flow from investing activities | ||
| Purchase of property and equipment | ||
| Deposit of restricted cash for bank guarantee, net of drawing | ||
| Net cash used in investing activities | ||
| Cash flow from financing activities | ||
| Repayments of lease liabilities | ||
| Proceeds from loans | ||
| Exercise of options and warrants by employees and consultants | ||
| Repayments of Convertible Loans (principal and interest) | ||
| Proceeds from exercise of investor warrants, net of finder fees | ||
| Net proceeds from issuance of units of securities in private placement | ||
| Repayment of royalties' liability to the Agricultural Research Organization | ||
| Net proceeds from issuance of shares in public offering | ||
| Proceeds from issuance of convertible loans | ||
| Proceeds from exercise of stock options | ||
| Net cash provided by financing activities | ||
| Exchange rate differences on cash and cash equivalents | ||
| Increase (decrease) in cash and cash equivalents | ||
| Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation, Beginning Balance | ||
| Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation, Ending Balance | ||
| Supplemental disclosure of significant non-cash transactions | ||
| Conversion of convertible loans into equity | ||
| Exercise of investor warrants by settlement of an outstanding debt | ||
| Reclassification of warrants as an equity instrument | ||
| Purchase of property under installment payment agreement | ||
| Recognition of right-of-use assets and lease liabilities | ||
| Supplemental disclosure of cash flow information | ||
| Taxes paid |
Loading...
